Cover Image

Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review

COVID-19 is considered as the third human coronavirus and has a high potential for transmission. Fast public health interventions through antibodies, anti-virals or novel vaccine strategies to control the virus and disease transmission have been extremely followed. SARS-CoV-2 shares about 79% genomi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Amirhossein SHEIKHSHAHROKH (Author), Reza RANJBAR (Author), Elnaz SAEIDI (Author), Farhad SAFARPOOR DEHKORDI (Author), Mohammad HEIAT (Author), Payam GHASEMI-DEHKORDI (Author), Hamed GOODARZI (Author)
Format:	Book
Published:	Tehran University of Medical Sciences, 2020-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Frequency of Resistance Genes in Salmonella enteritidis Strains Isolated from Cattle
by: Reza RANJBAR, et al.
Published: (2020)

In Silico Therapeutic Study: The Next Frontier in the Fight against SARS-CoV-2 and Its Variants
by: Calvin R. Wei, et al.
Published: (2024)

Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2
by: Muhammad Bilal, et al.
Published: (2020)

The coverage of SARS-CoV-2 vaccination and the willingness to receive the SARS-CoV-2 variant vaccine among employees in China
by: Xi-Ru Zhang, et al.
Published: (2023)

Therapeutic implications in patients with subacute thyroiditis in the SARS-CoV-2 era
by: Katrin Henke, et al.
Published: (2022)

Potential and Possible Therapeutic Effects of Melatonin on SARS-CoV-2 Infection
by: Evgeny Shchetinin, et al.
Published: (2022)

Anti-SARS-CoV-2 Natural Products as Potentially Therapeutic Agents
by: Cheorl-Ho Kim
Published: (2021)

Morphea after SARS-CoV2 vaccine
by: Giovanni Paolino, et al.
Published: (2023)

T cells in SARS-CoV-2 infection and vaccination
by: Arthur Young
Published: (2022)

Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2
by: Mohamad Hesam Shahrajabian, et al.
Published: (2021)

Expression and purification of SARS-CoV-2 receptor binding domain in Escherichia coli for diagnostic and therapeutic purposes
by: Hajarossadat Ghaderi, et al.
Published: (2024)

Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 helicase inhibitors: a systematic review of in vitro studies
by: Nimer Mehyar
Published: (2023)

Trends in MERS-CoV, SARS-CoV, and SARS-CoV-2 (COVID-19) Diagnosis Strategies: A Patent Review
by: José Adão Carvalho Nascimento Junior, et al.
Published: (2020)

Comparison of the Characteristics of Cytokine Storm and Immune Response Induced by SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections
by: Liu T, et al.
Published: (2021)

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic
by: Ali A. Rabaan, et al.
Published: (2020)

Bromelain: A potential therapeutic application in SARS-CoV-2 infected patients
by: Serkan Sayıner, et al.
Published: (2021)

New perspective towards therapeutic regimen against SARS-CoV-2 infection
by: Vartika Srivastava, et al.
Published: (2021)

Therapeutic Targeting of Innate Immune Receptors Against SARS-CoV-2 Infection
by: Mariya Farooq, et al.
Published: (2022)

Redox Status Is the Mainstay of SARS-CoV-2 and Host for Producing Therapeutic Opportunities
by: Anand Thirupathi, et al.
Published: (2022)

Carbon-based nanomaterials against SARS-CoV-2: Therapeutic and diagnostic applications
by: Sepideh Ahmadi, et al.
Published: (2023)

Targeting SARS-CoV-2 Variants with Nucleic Acid Therapeutic Nanoparticle Conjugates
by: Hanah F. Huber, et al.
Published: (2021)

Molecular Targets for Diagnostics and Therapeutics of Severe Acute Respiratory Syndrome (SARS-CoV)
by: Mavanur R. Suresh, et al.
Published: (2008)

Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review
by: Victoria Gil Martínez, et al.
Published: (2021)

Vaccine safety - is the SARS-CoV-2 vaccine any different?
by: Noam Tau, et al.
Published: (2021)

Eosinophilic fasciitis following SARS-CoV-2 vaccination
by: Victoria Lobo Antuña, MD, et al.
Published: (2023)

Vitiligo Repigmentation After SARS-CoV-2 Vaccine
by: Roberto Bustos-Macaya, et al.
Published: (2023)

Alopecia areata after SARS-CoV-2 vaccination
by: Margaret E. Scollan, MSc, et al.
Published: (2022)

Pregnancy and SARS - CoV - 2 vaccination: Unraveling the myths
by: Anita Yadav, et al.
Published: (2021)

SARS-CoV-2 vaccinations complicated by transverse myelitis
by: Josef Finsterer
Published: (2022)

SARS-CoV-2 reinfection and implications for vaccine development
by: Firzan Nainu, et al.
Published: (2020)

SARS-CoV-2 vaccine candidates in rapid development
by: Lifeng Li, et al.
Published: (2021)

SARS-CoV-2 Vaccination for Children-An Open Issue
by: Désirée Caselli, et al.
Published: (2021)

Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19)
by: Surjeet Verma, et al.
Published: (2020)

On the SARS-CoV-2 Variants
by: Fabio Scarpa, et al.
Published: (2024)

Cytokines and microRNAs in SARS-CoV-2: What do we know?
by: Fahimeh Zamani Rarani, et al.
Published: (2022)

Risk management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2
by: Syed Muhammad Ali Shah, et al.
Published: (2021)

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
by: Canrong Wu, et al.
Published: (2020)

Biosynthesis of Quantum Dots and Their Therapeutic Applications in the Diagnosis and Treatment of Cancer and SARS-CoV-2
by: Musa Moetasam Zorab, et al.
Published: (2023)

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2
by: Russell M. Petrak, et al.
Published: (2021)

Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19
by: Khan Sharun, et al.
Published: (2020)